Autism spectrum disorder (ASD) is one of the most researched and least understood conditions in medicine. Decades of study have produced no single explanation for why it develops, no universal treatment that works for everyone, and no shortage of families searching for options beyond what conventional care offers.
This article is written for those families. It covers what current research shows about the biology of ASD, why stem cell therapy has become a subject of serious scientific interest, and what the evidence actually supports — including where it falls short.
Autism is not one thing
ASD is a spectrum — a wide range of presentations that share some common features but differ significantly in severity, underlying biology, and how individuals experience and navigate the world. Difficulties with social communication, sensory processing, and repetitive behaviours are common across the spectrum, but the degree to which these affect daily life varies enormously from person to person.
This variability is important for understanding why no single intervention works for everyone with ASD. It is also why the emerging science around neuroinflammation and immune dysregulation in autism is significant — because it offers a biological mechanism that may apply to a meaningful subset of people with ASD, even if it does not apply to all.
The role of neuroinflammation in ASD
A growing body of research has identified chronic neuroinflammation as a feature present in a significant subset of individuals with ASD — with elevated pro-inflammatory cytokines found in the brains, cerebrospinal fluid, and blood of some people with ASD compared to neurotypical individuals.
Neuroinflammation doesn’t cause autism directly, but it appears to influence how the brain develops and functions — correlating with difficulties in attention, sensory processing, sleep, and gastrointestinal function.
Many individuals with ASD also show broader immune dysregulation, creating ongoing inflammatory signalling. Consistent enough across the literature to have generated serious scientific interest in immune-modulating therapies.
What UC-MSC therapy is being studied for in ASD
UC-MSCs — Umbilical Cord-Derived Mesenchymal Stem Cells — are not being studied as a way to change who someone is or alter the fundamental structure of the brain. The research question is more specific: can UC-MSCs reduce neuroinflammation and immune dysregulation in individuals with ASD, and does that reduction meaningfully affect co-occurring symptoms?
The biological rationale is straightforward. UC-MSCs have well-documented anti-inflammatory and immunomodulatory properties — they suppress pro-inflammatory cytokines, modulate overactive immune responses, and release neurotrophic factors that support neuronal health. In ASD patients with elevated inflammatory markers, reducing this inflammatory burden may improve the biological environment in which the brain operates.
The most plausible targets for improvement are not the core features of autism itself, but co-occurring conditions where inflammation and immune dysfunction are known contributors: sleep disturbances, gastrointestinal discomfort, attention difficulties, irritability, and sensory hypersensitivity
What the current evidence shows
Research is still developing, but what exists is worth taking seriously.
A 2022 systematic review found children receiving stem cell therapy showed meaningfully lower autism severity scores than control groups. Adverse events were mild and temporary. A separate study on UC-MSC infusions found half of participants improved across multiple measures over twelve months.
Responses vary, and more research is needed. But the evidence is consistent enough that dismissing it outright would be as inaccurate as overpromising it.
What to be cautious about
This is a space where overpromising is common. Families searching for options for their children are understandably motivated, and some clinics exploit that motivation with claims that are not supported by the evidence.
Stem cell therapy does not change the fundamental neurodevelopmental profile of a person with autism. It is not a cure, and any clinic that frames it as one is misrepresenting the science. The research interest is in whether it can reduce inflammatory burden and improve co-occurring symptoms — and even there, responses vary between individuals.
Equally important: not every child with ASD will have the elevated inflammatory markers or immune dysregulation that would make them a plausible candidate for this type of intervention. A responsible clinic will assess this before recommending treatment.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
References
- Qu J, Liu Z, Li L, et al. Efficacy and safety of stem cell therapy in children with autism spectrum disorders: a systematic review and meta-analysis. Frontiers in Pediatrics. 2022;10:897398. https://pmc.ncbi.nlm.nih.gov/articles/PMC9114801/
- Sun JM, Dawson G, Franz L, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Translational Medicine. 2020;9(10):1212–1220. https://pubmed.ncbi.nlm.nih.gov/32531111/
- Nabetani M, Mukai T, Taguchi A. Cell therapies for autism spectrum disorder based on new pathophysiology: a review. Cell Transplantation. 2023;32:09636897231163217. https://pmc.ncbi.nlm.nih.gov/articles/PMC10069005/
- Usui N, Kobayashi H, Shimada S. Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder. International Journal of Molecular Sciences. 2023;24(6):5487. https://pmc.ncbi.nlm.nih.gov/articles/PMC10049423